Last updated: October 30, 2026
BENDEKA, the branded bendamustine hydrochloride injection developed by Eagle Pharmaceuticals and commercialized by Teva Pharmaceuticals, is a differentiated oncology product in a mature generic market. Its commercial value comes from a ready-to-dilute formulation, a shorter administration time than TREANDA, and established use in chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Revenue has faced sustained pressure from generic bendamustine products, declining use of bendamustine in some treatment settings, payer controls, and competition from targeted therapies such as ibrutinib, venetoclax, BTK inhibitors, and anti-CD20 combinations.
The product remains commercially relevant because it is inexpensive relative to newer oncology agents and is used in community oncology and hospital settings. Its market position depends less on new patient growth than on formulation convenience, supply reliability, contracting, and the pace of generic price erosion.
What is BENDEKA and who markets it?
BENDEKA is a 100 mg/4 mL and 25 mg/1 mL bendamustine hydrochloride injection approved by the U.S. Food and Drug Administration under NDA 208194. It is administered as a short intravenous infusion after dilution.
The FDA label includes two principal indications:
- Chronic lymphocytic leukemia, or CLL.
- Indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with a rituximab-containing regimen or a regimen including rituximab.
Eagle Pharmaceuticals developed the formulation and entered into a commercial agreement with Teva. Teva has handled commercial distribution in the United States, while Eagle has retained economics through product sales, royalties, or other contractual payments depending on the reporting period and agreement structure. [1][2]
How does BENDEKA differ from TREANDA?
BENDEKA and TREANDA contain the same active ingredient, bendamustine hydrochloride, but they use different liquid formulations and administration procedures.
| Attribute |
BENDEKA |
TREANDA |
| Active ingredient |
Bendamustine hydrochloride |
Bendamustine hydrochloride |
| Dosage form |
Ready-to-dilute injection |
Powder for reconstitution or injection, depending on presentation |
| Typical infusion time |
Approximately 10 minutes after dilution |
Approximately 30 to 60 minutes, depending on product and protocol |
| Main commercial advantage |
Preparation and administration convenience |
Established historical brand |
| Market status |
Branded product with generic competition |
Original brand with extensive generic substitution |
| Primary users |
Community oncology, hospital outpatient settings |
Oncology treatment centers and hospitals |
The shorter infusion time can reduce chair utilization and pharmacy preparation requirements. That advantage has value, but it does not fully protect BENDEKA from substitution because generic products contain the same active ingredient and are generally reimbursed at lower prices.
What is the FDA regulatory and Orange Book status of BENDEKA?
BENDEKA is an FDA-approved prescription oncology product with an Orange Book-listed NDA. The product is not a biologic, so biosimilar regulation does not apply. Competitive entry occurs through abbreviated new drug applications, or ANDAs, for generic bendamustine hydrochloride injection.
The product’s regulatory profile is defined by:
| Regulatory item |
Status |
| FDA application |
NDA 208194 |
| Approval pathway |
505(b)(2) new drug application |
| Therapeutic category |
Antineoplastic alkylating agent |
| Dosage form |
Intravenous injection |
| Reference product |
BENDEKA |
| Generic pathway |
ANDA submissions for bendamustine hydrochloride injection |
| Biosimilar exposure |
None |
| Orange Book relevance |
Drug substance and formulation patent listings may affect ANDA timing |
The product’s approval was supported by pharmacokinetic and formulation data rather than by a new active pharmaceutical ingredient. That regulatory structure enabled FDA approval while allowing patent protection to focus on the liquid formulation and delivery characteristics. [1]
What patents protect BENDEKA?
The core U.S. patent estate has centered on Eagle’s liquid bendamustine formulation technology rather than composition-of-matter protection for bendamustine itself.
Publicly associated patent protection includes:
| Patent |
General subject matter |
Commercial relevance |
| U.S. Patent No. 8,445,524 |
Liquid bendamustine formulations and related pharmaceutical compositions |
Core formulation protection associated with BENDEKA |
| Related continuation or formulation patents |
Specific concentrations, excipients, stability, and administration characteristics |
Potential barriers to formulation-specific ANDAs |
U.S. Patent No. 8,445,524 is commonly associated with BENDEKA’s formulation protection. Its effective expiration has been reported in public patent and company materials as occurring around the end of the 2020s, subject to patent-term adjustment and the precise Orange Book listing. The patent does not provide composition-of-matter protection for bendamustine, which was developed long before BENDEKA.
The practical strength of the estate is therefore narrower than a new chemical entity estate. Generic applicants can challenge formulation claims, design around particular excipient combinations, or pursue products with different concentrations and preparation instructions.
How strong is the BENDEKA patent estate?
The estate is moderate rather than exceptionally strong.
Its strengths are:
- A formulation-specific patent strategy.
- FDA approval for a commercially useful liquid presentation.
- A meaningful administration-time advantage over older bendamustine formulations.
- Potential regulatory and litigation leverage against products that closely copy the protected formulation.
Its weaknesses are:
- No remaining composition-of-matter exclusivity for bendamustine.
- Multiple possible formulation designs.
- Generic manufacturers can use alternative excipients or concentrations.
- Market substitution can occur rapidly after approval if patents do not block launch.
- The clinical differentiation is operational rather than therapeutic.
The principal risk is that a generic applicant may obtain approval with a non-infringing formulation or prevail in Paragraph IV litigation before the listed patent expires.
When does BENDEKA lose exclusivity?
BENDEKA has already lost the exclusivity associated with being the only modern liquid bendamustine product. The relevant commercial question is not whether generic competition exists, but how quickly generic penetration and price erosion progress.
The product’s exclusivity timeline is:
| Milestone |
Timing |
| FDA approval of BENDEKA |
2015 |
| Early commercial expansion |
2015-2017 |
| Formulation-focused patent litigation risk |
Primarily during the late 2010s and early 2020s |
| Generic bendamustine competition |
Developed and introduced during the post-approval period |
| Core formulation patent horizon |
Around the end of the 2020s, subject to listed patent term |
| Long-term outlook |
Declining branded share and continued generic price pressure |
The six-month ANDA exclusivity period potentially available to a first filer would depend on the specific patent challenges and FDA approval sequence. Public market data do not establish a single, permanent first-filer position for all generic bendamustine products.
Which companies are challenging or competing with BENDEKA?
Competition comes from generic manufacturers, the original TREANDA franchise, and newer oncology regimens.
Relevant generic and branded competitors include:
- Teva Pharmaceuticals, which has participated in bendamustine commercialization and generic oncology products.
- Dr. Reddy’s Laboratories.
- Hikma Pharmaceuticals.
- Fresenius Kabi.
- Other injectable oncology manufacturers with FDA-approved or marketed bendamustine products.
- Generic products supplied through hospital and oncology wholesalers.
The competitive landscape is fragmented. Injectable oncology products compete on price, availability, vial sizes, pharmacy workflow, stability, and shortage risk. A generic manufacturer with reliable supply can gain share even if its formulation does not duplicate BENDEKA’s administration profile.
What Paragraph IV challenges and litigation affect BENDEKA?
Bendamustine formulation patents have been exposed to Paragraph IV challenges because the active ingredient itself is not protected by a current composition-of-matter patent. An ANDA applicant may certify that a listed patent is invalid, unenforceable, or not infringed.
A Paragraph IV filing can trigger:
- Patent litigation by the NDA holder or patent owner.
- A potential 30-month stay of FDA approval under the Hatch-Waxman Act.
- Settlement negotiations covering launch timing.
- A possible at-risk generic launch if litigation remains unresolved.
- Earlier erosion of branded share even before final patent expiration.
The commercial effect of litigation is often more important than the final judgment. A settlement that permits entry before nominal patent expiry can reduce BENDEKA’s value years earlier than an unchallenged patent would suggest.
Publicly available company disclosures have described generic competition and patent-related risk, but a definitive consolidated list of every historical Paragraph IV filer, settlement term, and launch restriction is not consistently reported across FDA, court, and company sources. [2][3]
What is the financial trajectory for BENDEKA?
BENDEKA’s financial trajectory follows the pattern of a mature specialty injectable:
- Rapid initial uptake after launch.
- Expansion based on conversion from TREANDA and operational savings.
- Peak or near-peak revenue before broad generic competition.
- Declining net sales as generic products enter.
- Continued residual revenue from contracted accounts, physician familiarity, and supply reliability.
Eagle has historically identified BENDEKA as a material commercial product and has reported product revenue, royalty revenue, or related economics tied to its marketed portfolio. The company’s filings show increasing pressure on mature oncology products as generic alternatives expand and treatment patterns change. Standalone BENDEKA economics are not always presented in a consistent format across reporting periods because commercial arrangements and revenue classifications can differ. [2][4]
What drives BENDEKA revenue?
Key revenue drivers include:
- Number of CLL and indolent lymphoma patients receiving bendamustine.
- BENDEKA’s share of total bendamustine use.
- Average selling price after rebates and discounts.
- Generic product availability.
- Teva’s contracting strategy.
- Hospital and group-purchasing-organization decisions.
- Treatment migration to BTK inhibitors, BCL-2 inhibitors, CAR-T therapy, and other targeted regimens.
- Bendamustine use in combination therapies, including rituximab-based treatment.
The product has a relatively low probability of returning to historical peak growth. Its remaining opportunity is defensive: preserving share in accounts that value shorter administration, predictable supply, and established clinical protocols.
How much revenue is exposed to generic competition?
Revenue exposure is high because BENDEKA does not have a protected new molecular entity and because bendamustine is available from multiple manufacturers.
The exposure has three dimensions:
| Exposure |
Impact |
| Price erosion |
Generic tenders and payer substitution reduce net price |
| Volume erosion |
Accounts switch to lower-cost injectable products |
| Therapeutic erosion |
New targeted treatments reduce bendamustine utilization |
The formulation advantage may support a premium in selected outpatient oncology accounts, but reimbursement generally limits how much of that premium can be retained. The product is more defensible where infusion-center efficiency has a measurable economic benefit.
What generic launch scenarios exist for BENDEKA?
Three scenarios are commercially plausible.
Delayed generic entry
Patent litigation or regulatory delays preserve branded share for a limited period. BENDEKA maintains a premium price, although contracting pressure still increases.
Authorized or coordinated generic entry
A generic enters under a settlement, license, or commercial agreement. Price erosion is meaningful, but the branded product may retain a portion of volume through account contracts.
Broad generic competition
Multiple manufacturers enter after patent expiry or successful litigation. BENDEKA becomes a secondary product, with the market determined by price, supply, and purchasing contracts.
The third scenario creates the greatest downside to branded revenue. Injectable oncology markets can experience rapid share shifts because hospital pharmacies and purchasing groups often prioritize cost and product availability.
What manufacturing and intellectual-property barriers protect BENDEKA?
Manufacturing is a secondary barrier compared with intellectual property, but sterile injectable production remains operationally demanding. Manufacturers must control:
- Sterility and endotoxin risk.
- Active-ingredient stability.
- Container-closure compatibility.
- Particulate matter.
- Dilution and storage conditions.
- Extractables and leachables.
- Reliable supply of bendamustine hydrochloride.
- FDA inspection and cGMP compliance.
BENDEKA’s formulation patents may deter direct copying, but they do not prevent all bendamustine products. Manufacturing complexity can reduce the number of credible competitors, yet established injectable manufacturers have the infrastructure to enter once commercial returns justify the investment.
How does BENDEKA compare with other lymphoma drugs?
BENDEKA competes in an increasingly segmented market.
| Product class |
Examples |
Effect on BENDEKA |
| Older chemotherapy |
Bendamustine, chlorambucil |
Direct or complementary competition |
| Anti-CD20 antibodies |
Rituximab, obinutuzumab |
Frequently used in combination or alternative regimens |
| BTK inhibitors |
Ibrutinib, acalabrutinib, zanubrutinib |
Reduce chemotherapy use in selected CLL and lymphoma patients |
| BCL-2 inhibitors |
Venetoclax |
Compete in CLL and combination treatment |
| Cellular therapies |
CAR-T products |
Affect later-line lymphoma treatment |
| Generic injectables |
Generic bendamustine products |
Direct price and volume threat |
BENDEKA remains attractive when oncologists want a familiar cytotoxic backbone at a lower cost than targeted agents. Its strategic position is weaker in treatment lines where oral targeted agents have become standard.
Key Takeaways
- BENDEKA is a branded liquid bendamustine injection marketed by Teva and developed by Eagle Pharmaceuticals.
- Its main differentiation is a short infusion and simplified preparation, not a novel active ingredient.
- The relevant patent estate is formulation-based and materially weaker than composition-of-matter protection.
- Generic competition is the primary commercial threat.
- Revenue has moved from launch-driven growth toward mature-product decline.
- Newer CLL and lymphoma therapies create long-term therapeutic erosion in addition to generic price pressure.
- Manufacturing complexity may limit the number of reliable competitors but does not eliminate generic entry risk.
- The most important valuation variables are generic launch timing, net price erosion, Teva contracting, bendamustine utilization, and Eagle’s retained economics.
FAQs
Is BENDEKA still under patent protection?
Formulation-related patent protection has extended beyond initial FDA approval, with the principal patent horizon generally associated with the end of the 2020s, subject to the precise Orange Book listing and patent-term adjustment.
Is BENDEKA a biologic or a biosimilar product?
No. BENDEKA is a small-molecule oncology drug. Its competitors enter through the ANDA generic pathway, not the biosimilar pathway.
Can a generic copy BENDEKA’s 10-minute infusion?
A generic applicant must meet FDA requirements for its own formulation and labeling. It may pursue similar administration instructions, but patent scope and formulation design determine whether the product can lawfully copy specific features.
Does BENDEKA have composition-of-matter protection?
No current commercial protection is based on new chemical entity exclusivity for bendamustine. The principal protection has focused on formulation and delivery characteristics.
What is the largest long-term risk to BENDEKA revenue?
The largest risk is the combination of generic price erosion and declining bendamustine utilization as physicians shift eligible CLL and lymphoma patients to targeted therapies.
References
-
U.S. Food and Drug Administration. (2015). BENDEKA (bendamustine hydrochloride) injection prescribing information. FDA.
-
Eagle Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Eagle Pharmaceuticals, Inc. (2023). Annual report on Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,445,524: Liquid formulations of bendamustine. USPTO.
